Dr. Reddy's Laboratories unveils Vigabatrin Tablets, USP in the US Market
3 February 2021 -

Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Tuesday the availability of Vigabatrin Tablets USP in 500 mg tablets in a bottle count size of 100 in the US market.

According to the company, Vigabatrin Tablets USP in 500 mg is the therapeutic equivalent generic version of the US Food and Drug Administration (USFDA) approved Sabril (vigabatrin) Tablets, USP. The Sabril brand and generic had US sales of approximately USD141m MAT for the most recent 12 months ending in December 2020, according to IMS Health.

The company's Vigabatrin Tablets USP is designated as a Competitive Generic Therapy (CGT) by the US FDA, says Marc Kikuchi, CEO, North America Generics. With a CGT designation, it has 180-day CGT exclusivity to market this product.

Vigabatrin, brand name Sabril, is a medication used to treat epilepsy. It works by inhibiting the breakdown of γ-aminobutyric acid (GABA). It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors, concluded the company.